We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

17 hedge funds and large institutions have $633K invested in Titan Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 17 → 17 (0)

0% more ownership

Funds ownership: 0.32% → 0.33% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

20% less capital invested

Capital invested by funds: $787K → $633K (-$155K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$22.7K
2
Renaissance Technologies
Renaissance Technologies
New York
+$153

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$1.27K
2
TRCT
Tower Research Capital (TRC)
New York
-$31
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$15

TTNP Hedge Fund Activity: Q2 2023 in Review

17 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2023, worth a combined $633K — down 20% from $787K a quarter earlier.

Fund positioning in TTNP was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $22.7K. The largest seller was UBS Group, exiting entirely with an estimated $1.27K sold.

  • 17 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $633K of Titan Pharmaceuticals stock for Q2 2023, down 20% quarter-over-quarter.
  • 1 fund opened new Titan Pharmaceuticals positions in Q2 2023 and 1 closed out, a net change of 0 holders.
  • The largest Titan Pharmaceuticals buyer in Q2 2023 was Citadel Advisors, an estimated $22.7K added.
  • The largest Titan Pharmaceuticals seller in Q2 2023 was UBS Group, an estimated $1.27K sold.

Based on aggregated 13F filings for Q2 2023.